Pharmadrug Inc. operates as a specialty pharmaceutical company. The company focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. It also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions. It has a license agreement with Southwest Research Institute. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. Pharmadrug Inc. was incorporated in 2011 and is based in Toronto, Canada.…
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Pharmadrug (CNSX: PHRX) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 0.0050 CAD on 19 November 2026, down 75.0% over 52 weeks. Its 52-week range is 0.0050 CAD to 0.0200 CAD, and it trades at the bottom of that range.
Its market capitalisation is 671.07K CAD.
Pharmadrug reports return on equity of 21.7% and an operating margin of 0.0%.
Its debt exceeds its cash by 1.78M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.